Study Finds Infectious Diseases Have Surged Post C
Post# of 88
(Total Views: 128)
Posted On: 06/26/2024 5:09:24 PM
Study Finds Infectious Diseases Have Surged Post COVID-19 Pandemic
New research has determined that the global effect of the coronavirus pandemic observed over the last four years has led to a heightened surge of other infectious illnesses. The research was conducted by Airfinity, a data and analytics company based in the United Kingdom, which is focused on monitoring and predicting trends in global public health and disease.
This observation suggests that measures imposed by governments globally allowed SARS-CoV-2 to proliferate and infect millions created conditions for even more damage to be done.
For its research, the company conducted an analysis which determined that globally, there had been a resurgence of at least 13 infectious illnesses, with cases reported being higher than those recorded prior to the pandemic in a number of regions. The analysis also found that more than 40 nations or territories had reported cases of at least one infectious illness increasing to levels higher than prepandemic baselines.
The figures provided by Airfinity showed that diseases such as dengue, cholera, polio, tuberculosis, influenza and invasive group A streptococcal disease had risen. Other illnesses that are harsher on immunocompromised individuals and children that have seen cases increase include pertussis, chickenpox, respiratory syncytial virus and measles.
The significant increase in these illnesses beyond prepandemic levels is troubling, with the company positing that long COVID may play a role in their increase.
Research has shown that long COVID affects almost every organ in the body, with the National Academy of Sciences documenting more than 200 symptoms of the illness. In America alone, about one in five individuals has experienced long COVID, which adds up to 50 million individuals. Currently, the prevalence of this illness is roughly 7%.
The long-term effects of this illness are significant and probably lifelong. For instance, it heightens an individual’s risk of heart attacks as well as increases the risk of a number of metabolic and neurological issues that contribute to the overall deterioration of an individual’s health.
It doesn’t help either that children who have been exposed repeatedly to the coronavirus and other respiratory pathogens in poorly ventilated and crowded schools are largely uninvestigated.
Experts in the field argue that the only effective way to fight the coronavirus and other disease-causing pathogens, be it rare or common, is to test more individuals, track identified cases and isolate if need be. They also propose that N95 masks be used as well as ensuring indoor air is clean.
Additionally, public health infrastructure and healthcare systems around the globe need to be funded properly so they can function as intended.
The efforts being undertaken by enterprises to develop immunotherapies against various infectious diseases, such as Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), could provide viable ways to treat some of these rapidly reemerging infectious diseases.
NOTE TO INVESTORS: The latest news and updates relating to Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) are available in the company’s newsroom at https://ibn.fm/SCNI
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
New research has determined that the global effect of the coronavirus pandemic observed over the last four years has led to a heightened surge of other infectious illnesses. The research was conducted by Airfinity, a data and analytics company based in the United Kingdom, which is focused on monitoring and predicting trends in global public health and disease.
This observation suggests that measures imposed by governments globally allowed SARS-CoV-2 to proliferate and infect millions created conditions for even more damage to be done.
For its research, the company conducted an analysis which determined that globally, there had been a resurgence of at least 13 infectious illnesses, with cases reported being higher than those recorded prior to the pandemic in a number of regions. The analysis also found that more than 40 nations or territories had reported cases of at least one infectious illness increasing to levels higher than prepandemic baselines.
The figures provided by Airfinity showed that diseases such as dengue, cholera, polio, tuberculosis, influenza and invasive group A streptococcal disease had risen. Other illnesses that are harsher on immunocompromised individuals and children that have seen cases increase include pertussis, chickenpox, respiratory syncytial virus and measles.
The significant increase in these illnesses beyond prepandemic levels is troubling, with the company positing that long COVID may play a role in their increase.
Research has shown that long COVID affects almost every organ in the body, with the National Academy of Sciences documenting more than 200 symptoms of the illness. In America alone, about one in five individuals has experienced long COVID, which adds up to 50 million individuals. Currently, the prevalence of this illness is roughly 7%.
The long-term effects of this illness are significant and probably lifelong. For instance, it heightens an individual’s risk of heart attacks as well as increases the risk of a number of metabolic and neurological issues that contribute to the overall deterioration of an individual’s health.
It doesn’t help either that children who have been exposed repeatedly to the coronavirus and other respiratory pathogens in poorly ventilated and crowded schools are largely uninvestigated.
Experts in the field argue that the only effective way to fight the coronavirus and other disease-causing pathogens, be it rare or common, is to test more individuals, track identified cases and isolate if need be. They also propose that N95 masks be used as well as ensuring indoor air is clean.
Additionally, public health infrastructure and healthcare systems around the globe need to be funded properly so they can function as intended.
The efforts being undertaken by enterprises to develop immunotherapies against various infectious diseases, such as Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), could provide viable ways to treat some of these rapidly reemerging infectious diseases.
NOTE TO INVESTORS: The latest news and updates relating to Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) are available in the company’s newsroom at https://ibn.fm/SCNI
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
(0)
(0)